Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America

Key Points

• Erenumab significantly improved patient-reported outcomes for episodic migraine patients across various regions.
• The change in migraine frequency was particularly noteworthy in participants from Asia, the Middle East, and Latin America.
• Assessment utilized clinical trial data to evaluate patient experiences following erenumab treatment.
• Findings highlight the need for region-specific treatment strategies for managing episodic migraine effectively.